RPRX Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma (NASDAQ:RPRX) executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage. Speaking during a firesid

Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.

Royalty Pharma has delivered a strong share price run in recent years, which naturally puts fresh attention on what investors are paying for its earnings today. With the stock now around US$58.52, the key issue is how that outcome lines up with the underlying profit engine of its royalty portfolio. Over the last 3 years, Royalty Pharma has returned about 136.3%, which increases the stakes on whether its current earnings base can carry that kind of share price progress. The recent US$7.5...

Royalty Pharma (RPRX) is set to present at the Bank of America Global Healthcare Conference in London on September 23, 2026. The appearance will put its biopharmaceutical royalty model back in front of institutional investors. Recent trading hints at cooling momentum in Royalty Pharma’s share price in the very short term, with a 30-day share price return down 4.6%, even as the 90-day share price return of 7.8% and 1-year total shareholder return of 64.6% point to a much stronger longer-run...

Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in […]

Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.

On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1). The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia. Read Also: A Wall St

On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma’s second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company […]

Merck shares rose on growing confidence in its cancer pipeline, while Royalty Pharma hit a record high as Ziihera’s FDA approval strengthened its royalty opportunity.

In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a […]

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares may now be closer to fairly priced than a clear bargain. Over five years, Zealand Pharma has returned 90.3%, which puts current buyers in a different position to those who entered earlier in the story. The recent $100 million royalty deal with Royalty Pharma can support funding for rusfertide and other priorities. Reliance on...

Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase and sale deal with Royalty Pharma linked to rusfertide, a potential treatment for polycythemia vera. The agreement transfers Zealand Pharma's economic interests related to rusfertide, including potential future royalty rights. It also provides new funding that management plans to redeploy toward the company's key priorities...

Royalty receipts surged 14% as guidance raised for second consecutive quarter.

Revolution Medicines Inc (RVMD) reports paradigm-changing Phase 3 results and a robust $3.9 billion cash position to fuel its commercial launch and expansive pipeline.

Revolution Medicines (NASDAQ:RVMD) said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer. The company

Royalty Pharma (NASDAQ:RPRX) raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its development-stage pipeline. Chief Executive Officer Pablo Legorreta said the company delivered 6% grow

Royalty Pharma PLC (RPRX) reports 14% total receipts growth and raises full-year 2026 guidance for the second consecutive quarter.

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Royalty Pharma dividend decision puts income focus in the spotlight Royalty Pharma (RPRX) has affirmed a third quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10 to shareholders of record as of the close on August 14. See our latest analysis for Royalty Pharma. Royalty Pharma’s dividend affirmation comes after a strong run in the stock, with the share price at $59.03 and a year to date share price return of 51.9% alongside a 1 year total shareholder return of...

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.